Capecitabine-Temozolomide (CAPTEM) in advanced Grade 2 and grade 3 Neuroendocrine neoplasms (NENs) – benefits of chemotherapy in NENs with significant 18FDG uptake

2020 ◽  
Author(s):  
Vikas Ostwal ◽  
Sandip Basu ◽  
Prabhat Bhargava ◽  
Minit Shah ◽  
Rahul Vithalrao Parghane ◽  
...  
Keyword(s):  
Neuroendocrine Neoplasms ◽  
18Fdg Uptake ◽  
Grade 3

Giant Primary Neuroendocrine Neoplasms of the Liver: Report of 2 Cases With Molecular Characterization

2019 ◽  
Vol 27 (8) ◽  
pp. 893-899
Author(s):  
Laura G. Pastrián ◽  
Ignacio Ruz-Caracuel ◽  
Raul S. Gonzalez
Keyword(s):  
World Health Organization ◽  
Neuroendocrine Tumor ◽  
Large Cell ◽  
The Other ◽  
World Health ◽  
Neuroendocrine Neoplasms ◽  
Molecular Testing ◽  
Well Differentiated ◽  
Grade 3 ◽  
Health Organization

Primary neuroendocrine neoplasms of the liver have occasionally been reported in the liver, though many reports do not convincingly exclude metastases. In this article, we report 2 “giant” hepatic neuroendocrine lesions without evidence of a primary elsewhere after clinical workup. One occurred in a 21-year-old male; the lesion was a large cell neuroendocrine carcinoma measuring 24 cm. The patient died of disease in 10 months. The other occurred in a 25-year-old patient, was 18 cm wide, and was diagnosed as a well-differentiated neuroendocrine tumor, World Health Organization grade 3. The patient died of disease after 30 months. Molecular testing demonstrated only the presence of TP53 mutations in common. These cases expand our knowledge of seemingly primary neuroendocrine neoplasms of the liver, in particular, giant cases measuring more than 8 cm. Guidelines for clinical workup and therapy for these lesions remain unclear, but future thorough workup of such cases is necessary for specific characterization.

scholarly journals Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors

2020 ◽  
Vol 9 (11) ◽  
pp. 3679
Author(s):  
Anna Yordanova ◽  
Hans-Jürgen Biersack ◽  
Hojjat Ahmadzadehfar
Keyword(s):  
Molecular Imaging ◽  
Neuroendocrine Tumors ◽  
Pet Imaging ◽  
Neuroendocrine Neoplasms ◽  
New Agents ◽  
Positron Emission ◽  
Tailored Approach ◽  
Grade 3 ◽  
New Applications ◽  
Chemokine Receptor 4

Neuroendocrine neoplasms make up a heterogeneous group of tumors with inter-patient and intra-patient variabilities. Molecular imaging can help to identify and characterize neuroendocrine tumors (NETs). Furthermore, imaging and treatment with novel theranostics agents offers a new, tailored approach to managing NETs. Recent advances in the management of NETs aim to enhance the effectiveness of targeted treatment with either modifications of known substances or the development of new substances with better targeting features. There have been several attempts to increase the detectability of NET lesions via positron emission tomography (PET) imaging and improvements in pretreatment planning using dosimetry. Especially notable is PET imaging with the radionuclide Copper-64. Increasing interest is also being paid to theranostics of grade 3 and purely differentiated NETs, for example, via targeting of the C-X-C motif chemokine receptor 4 (CXCR4). The aim of this review is to summarize the most relevant recent studies, which present promising new agents in molecular imaging and therapy for NETs, novel combination therapies and new applications of existing molecular imaging modalities in nuclear medicine.

Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour

2014 ◽  
Vol 25 (5) ◽  
pp. 1375-1383 ◽  
Author(s):  
Dong Wook Kim ◽  
Hyoung Jung Kim ◽  
Kyung Won Kim ◽  
Jae Ho Byun ◽  
Ki Byung Song ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Neuroendocrine Tumour ◽  
Neuroendocrine Neoplasms ◽  
Enhanced Ct ◽  
Grade 3

scholarly journals Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms

2019 ◽  
Vol 60 (7) ◽  
pp. 882-891 ◽  
Author(s):  
Najeff Waseem ◽  
Carina Mari Aparici ◽  
Pamela L. Kunz
Keyword(s):  
Neuroendocrine Neoplasms ◽  
Grade 3

The Spectrum of Neuroendocrine Tumors: Histologic Classification, Unique Features and Areas of Overlap

2015 ◽  
pp. 92-103 ◽  
Author(s):  
David S. Klimstra ◽  
Himisha Beltran ◽  
Rogerio Lilenbaum ◽  
Emily Bergsland
Keyword(s):  
Neuroendocrine Tumors ◽  
Prostate Gland ◽  
Neuroendocrine Differentiation ◽  
Large Cell ◽  
Genetic Alterations ◽  
Neuroendocrine Cells ◽  
Neuroendocrine Neoplasms ◽  
Platinum Based Chemotherapy ◽  
Well Differentiated ◽  
Grade 3

Neuroendocrine neoplasms are diverse in terms of sites of origin, functional status, and degrees of aggressiveness. This review will introduce some of the common features of neuroendocrine neoplasms and will explore the differences in pathology, classification, biology, and clinical management between tumors of different anatomic sites, specifically, the lung, pancreas, and prostate. Despite sharing neuroendocrine differentiation and histologic evidence of the neuroendocrine phenotype in most organs, well-differentiated neuroendocrine tumors (WD-NETs) and poorly differentiated neuroendocrine carcinomas (PD-NECs) are two very different families of neoplasms. WD-NETs (grade 1 and 2) are relatively indolent (with a natural history that can evolve over many years or decades), closely resemble non-neoplastic neuroendocrine cells, and demonstrate production of neurosecretory proteins, such as chromogranin A. They arise in the lungs and throughout the gastrointestinal tract and pancreas, but WD-NETs of the prostate gland are uncommon. Surgical resection is the mainstay of therapy, but treatment of unresectable disease depends on the site of origin. In contrast, PD-NECs (grade 3, small cell or large cell) of all sites often demonstrate alterations in P53 and Rb, exhibit an aggressive clinical course, and are treated with platinum-based chemotherapy. Only WD-NETs arise in patients with inherited neuroendocrine neoplasia syndromes (e.g., multiple endocrine neoplasia type 1), and some common genetic alterations are site-specific (e.g., TMPRSS2-ERG gene rearrangement in PD-NECs arising in the prostate gland). Advances in our understanding of the molecular basis of NETs should lead to new diagnostic and therapeutic strategies and is an area of active investigation.

Abstract 3429: Genetic analysis of pancreatic neuroendocrine neoplasms grade 3

2019 ◽  
Author(s):  
Nobuyuki Kakiuchi ◽  
Kenichi Yoshida ◽  
Yusuke Shiozawa ◽  
Akira Yokoyama ◽  
Keisuke Kataoka ◽  
...  
Keyword(s):  
Genetic Analysis ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Grade 3

scholarly journals Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology

Pancreas ◽  
2017 ◽  
Vol 46 (3) ◽  
pp. 296-301 ◽  
Author(s):  
Nitya Raj ◽  
Emily Valentino ◽  
Marinela Capanu ◽  
Laura H. Tang ◽  
Olca Basturk ◽  
...  
Keyword(s):  
Treatment Response ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Grade 3

scholarly journals Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Abir Salwa Ali ◽  
Aurel Perren ◽  
Cecilia Lindskog ◽  
Staffan Welin ◽  
Halfdan Sorbye ◽  
...  
Keyword(s):  
Neuroendocrine Neoplasms ◽  
Protein Biomarkers ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Candidate Protein ◽  
Grade 3
Sign in / Sign up

Export Citation Format

Share Document